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Inadequate platelet inhibition by clopidogrel has been associated with increased rates of recurrent ischemic events due to stent thrombosis. 4-7 Several factors have been speculated to be involved in this mechanism. However, today we know that the major factors contributing to this variability of response are related with clopidogrel metabolism as a result of various factors. 8, 9 A variety of tests have been proposed for the evaluation of platelet inhibition by clopidogrel and aspirin, while Light Transmitted Aggregometry is considered to be the gold standard method. 10, 11 Recently, it was shown that residual platelet reactivity (RPR) to clopidogrel therapy, measured with VerifyNow, a point-of-care assay system with excellent correlation with Light Transmitted Aggregometry, is associated with post-discharge events following PCI with drug-eluting stents. 12 Indeed, angiographically determined coronary thrombus burden (TB) has been found to be an independent predictor of major adverse cardiac events (MACEs), infarct-related artery patency and stent thrombosis in patients presented with ST-segment elevation myocardial infarction (STEMI) treated with PCI. 3 Current recommendations for pPCI in patients with AMI suggest that the time from first-medical-contact (FMC) to balloon inflation should not exceed 2 h. 13 Yet, a significant number of patients might surpass the time limit mainly due to unexpected delays (eg, traffic jam), while in transportation from a hospital not performing pPCI. 14 In contrast, in order to achieve adequate platelet inhibition, an elapsed time of 2 h after loading with 600 mg of clopidogrel is required. This is not achieved in most patients undergoing pPCI. These patients might possibly be more vulnerable to the effect of inadequate platelet inhibition.
Although there is evidence connecting inadequate platelet inhibition and adverse outcome in patients with ACS, the association between the coronary angiographic characteristics and the degree of platelet inhibition in patients with ACS has not been thoroughly investigated. It is conceivable that platelet inhibition might be even more important when reperfusion is not achieved early. In this clinical scenario, platelet aggregation might increase to a greater degree leading to more frequent angiographic and clinical events.
In the present study, we hypothesized that in patients with STEMI who underwent an unexpectedly delayed catheterization, a lower degree of platelet inhibition after loading with clopidogrel might be associated with larger intracoronary TB. Furthermore, we examined the impact of the observed platelet inhibition on myocardial perfusion and outcome after pPCI for AMI.
Methods

Study Population
Patients with STEMI who were eligible for pPCI were initially considered as candidates for the registry. Seventy-four patients who met the study inclusion criteria were finally included in the study. Our hospital participates in the Greek National Program for AMI. Thus, twice a week our catheterization laboratory is one of the centers responsible for providing 24-h coverage for our city. This is performed in addition to the daily coverage for any ACS presenting to the emergency department of our hospital. All subjects gave informed consent before entering the study, which was approved by the Institutional Scientific Committee.
Inclusion Criteria
Over a 3-year period, any patient with STEMI who was eligible for pPCI was initially considered as a candidate for the registry. Patients with STEMI were either transferred from a referring hospital or presented directly to our hospital through the National Emergency Medical System. Those who unexpectedly failed to achieve the goal of an FMC-to-balloon time of less than 2 h were finally included in the registry (ie, all patients included had an FMC-to-balloon time of >2 h).
Antiplatelet Management
As per usual clinical routine in the participating hospitals, a loading dose of 600 mg of clopidogrel is given to all patients at FMC if they are considered to be candidates for transportation for primary PCI. In patients already receiving clopidogrel for more than 1 week, the initial loading dose is reduced to 300 mg. Subsequently, 75 mg of clopidogrel was given daily. All patients were administered 325 mg of acetylsalicylic acid from day 1 up to day 7. A maintenance dose of 100 mg of aspirin per day was given after day 7.
Exclusion Criteria
The exclusion criteria of the study included: (1) FMC-to-balloon time of <2 h; (2) patients who had received glycoprotein IIb/IIIa inhibitors less than 1 week prior to coronary catheterization; (3) known hypercoagulable state; (4) patients receiving coumarin treatment; (5) subjects with a declared allergy to clopidogrel; and (6) administration of thrombolysis for the current ischemic event.
Coronary Angiography - pPCI All patients underwent a standard coronary angiography and pPCI, if appropriate. Coronary interventions were performed according to current standard guidelines. 13 Subsequently to the advancement of the guide wire through the lesion and the evaluation of myocardial flow and myocardial perfusion, the interventionalist performed a manual aspiration of intracoronary thrombus in all patients.
All patients received stents, while the type of stent implanted was left at the discretion of the operator. The use of a glycoprotein IIb/IIIa inhibitor was initiated after completion of diagnostic catheterization and prior to intervention. It was administered only in patients with total occlusion after successful crossing of the lesion with the guide wire. Thus, all patients included in the analysis were not on IIb/IIIa inhibitors while undergoing diagnostic coronary injection. Therefore, the coronary angiogram, which was used for the evaluation of flow and perfusion characteristics, was not affected by infusion of IIb/IIIa inhibitors. Intravenous bolus unfractionated heparin (100 IU/kg) was given during coronary interventions while β-blockers and statins were given to all patients afterwards.
Angiographic TB Analysis
Culprit lesion was determined by angiographic and electrocardiographic features. The angiographic view that best demonstrated the thrombus was selected for analysis. In order to grade the intracoronary thrombus, we used the following classification: 3 (1) NDT: no detectable thrombus; (2) thrombus Grade A: definite thrombus with greatest dimensions ≤1/2 the vessel diameter; (3) thrombus Grade B: definite thrombus with greatest linear dimension >1/2 but <2 RPR in Delayed Primary PCI vessel diameters; and (4) thrombus Grade C: definite thrombus with greatest linear dimension ≥2 vessel diameters. In patients with total occlusion (unable to assess TB due to total vessel occlusion), thrombus was classified into one of the other categories after flow achievement with guide-wire crossing of the occlusion. When Thrombolysis In Myocardial Infarction (TIMI) flow remained zero after crossing of the wire, the patient was classified as having thrombus Grade C. Patients with dissection and NDT or ambiguous findings of thrombus (haziness or irregular lesion contour) were excluded from the analysis.
In order to more comprehensively evaluate and associate the impact of the presence of angiographic large TB (LTB) with a series of covariates, patients were re-assigned into 2 groups: (1) small TB (STB) group: patients with thrombus Grades A and B; and (2) LTB group: patients with thrombus Grade C.
Coronary and Myocardial Perfusion
In order to evaluate the coronary perfusion abnormalities after stent deployment, TIMI-flow and Myocardial Perfusion (Myocardial Blush [MB]) were assessed post-PCI. TIMI-flow grades were assessed as previously described. 15 Ten seconds of recording was required to allow some filling of the venous system in order to evaluate the washout phase of contrast dye. MB was graded according to the dye-density score proposed by van't Hof et al: 16 Grade-0: no MB or contrast density; Grade-1: minimal MB or contrast density; Grade-2: moderate MB or contrast density but less than that obtained during angiography of a contralateral or ipsilateral non -infarctrelated coronary artery; and Grade-3: normal MB or contrast density, comparable with that obtained during angiography of a contralateral or ipsilateral non-infarct-related coronary artery.
Since any TIMI-flow <3 is considered inadequate, we reclassified Post-PCI-TIMI-flow grades 0,1,2 as "impaired" TIMI-flow and grade 3 as "normal". Likewise, post-PCI MB grades 0,1,2 were classified together as "impaired" MB and grade 3 as "normal".
Two experienced interventionalists, blinded to the patient's VerifyNow results, assessed all the above parameters (evaluation of angiographic TB, coronary and myocardial perfusion).
RPR Assessment
RPR assessment for clopidogrel was performed using the VerifyNow system (Accumetrics, SanDiego, CA, USA). The test is intended to calculate platelet P2Y12 receptor blockade in patients already receiving clopidogrel. Test results are expressed, using a proprietary algorithm, as absolute P2Y12-Reaction-Units (PRU) for clopidogrel. Higher PRU levels reflect higher P2Y12-mediated reactivity. Results include a calculation of percent inhibition of platelet reactivity (%-Inhibition) via the formula: 100*[(BASE -RESULT)/BASE]. "Base" result is an independent measurement based on the rate and extent of platelet aggregation from thrombin receptors (PAR-1 and PAR-2) and it serves as an estimate of a patient's baseline platelet function independent of P2Y12 receptor inhibition. "Base" result is normalized by the assay to report units that are equivalent to baseline PRU. Moreover, platelet dysfunction consistent with aspirin was evaluated with the VerifyNow system; results were expressed in Aspirin Reaction Units (ARU).
Whole blood was collected prior to catheterization, according to the manufacturer's instructions, using a 21-gauge needle. The first 2 ml of blood was placed into a tube that was discarded. Subsequently, the collected blood was transferred into two 1.8-ml blood collection tubes containing 0.2 ml buffered 3.2% sodium citrate solution. Patients' blood samples were analyzed 15±1 min after collection (the manufacturer suggests that analysis should be conducted at least after 10 min of blood collection, but no later than 2 h).
Endpoints
The primary endpoint of the study was the detection of difference in platelet inhibition between patients with different intracoronary thrombus grade. Additionally, myocardial TIMI-flow, MB after pPCI was evaluated in relation to RPR. Clinical events were also recorded.
Clinical Follow up
In this study, we registered the incidence of MACE from the enrolled patients. An inquiry for MACE was conducted for every patient at 3-month intervals from the enrollment in the study. Clinical follow up was performed either by a clinical visit or by telephone contact to the patient or the referring physician. MACEs were defined as the following: death (any death not documented to be related to extracardiac causes), myocardial infarction and stroke (documented by hospital records).
Sample Size Estimation
The size of the patient population (n) was calculated as described by Pocock, 17 using the formula: n ={f(a,b) × [p1× (100 -p1) + p2 × (100 -p2)]}÷{p2 -p1} 2 , where p1 is the %-inhibition of platelet reactivity in subjects with a normal response to clopidogrel; p2 is the expected %-inhibition of platelet reactivity in subjects with an inadequate response to clopidogrel; a, type-I-error; b, type-II-error; f(a,b) is a function of a and b provided by reference statistical tables.
We conducted a pilot study in order to facilitate sample size estimation. In patients with AMI but without an angiographic large thrombus, PRU and %-Inhibition of Platelet Reactivity were measured. In our pilot population, %-Inhibition was 32.0±18.3%. In the report by Godino et al, 18 lowresponders to clopidogrel were found to reach the level of 70% lower %-Inhibition compared to high-responders.
If we assume that, in our study, patients with a large intracoronary thrombus would manifest a 70% reduction in %-Inhibition from those with a small thrombus, the sample size required to detect a statistically significant difference would be a minimum of 64 patients.
Statistical Analysis
Continuous variables are presented as mean ± standard deviation unless stated otherwise. The non-parametric KolmogorovSmirnov test and histograms were used to assess the normality of continuous variables distribution. Differences between groups were evaluated by 2-tailed, independent samples Student's t-test or 1-way analysis of variance for continuous variables and by the X 2 for categorical variables. The MonteCarlo exact test was used when the expected number was not greater than 5 in 80% of the cells or not greater than 1 in all cells. Multivariate logistic regression analysis (enter method with forced entry of independent variables) was performed to estimate independent associations after adjustment for confounding factors. Receiver operating characteristic (ROC) curve analysis was conducted to identify any cut-off point in PRU levels that correlates with larger TB. Cox-Regression (stepwise backward conditional method) was applied to
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Results
Overall 320 patients were initially considered eligible. Out of them, we excluded 216 patients because FMC-balloon time was less than 2 h, 20 patients due to glycoprotein IIb/IIIa intake less than 1 week prior to catheterization, 10 patients because of receiving coumarin treatment, and 2 patients due to a declared allergy to clopidogrel. Finally, none of the patients had a known hypercoagulable state, or had been administered thrombolysis for the current ischemic event.
From this population, 74 consecutive patients, who met the study criteria, were finally enrolled. After diagnostic catheterization, a total of 3 did not undergo pPCI because they were considered better candidates for coronary artery bypass graft surgery; these patients were not excluded from the study. After definition of the culprit lesion and selection of the most appropriate angiographic view, Grade-A TB was detected in 10 patients (13.5%), Grade-B in 26 patients (35.1%), while Grade-C thrombus was observed in 38 patients (51.4%).
Demographic and clinical characteristics were comparable between all 3 TB groups except for gender distribution (P= 0.016) and culprit lesion location in the coronary artery tree; detailed results of the univariate analysis are presented in Table 1 .
TB Volume and Platelet Inhibition by Clopidogrel
When the degree of platelet inhibition by clopidogrel was examined in the 3 TB groups, ANOVA analysis revealed a significant difference: PRU levels for Grade-A, B, and C TB-groups were 174.1±91. 5, 196 .23±113.4 and 252.8±107.8, respectively; P=0.044. Moreover, a significant linear trend for PRU to increase with greater TB was observed; P=0.015. Likewise, %-Inhibition (from baseline) of platelet reactivity differed significantly among the 3 groups: 36.7%±28.5%, 31.8%±30.74%, and 17.1%±25.6% (P=0.048) for Grade-A, B and C TB-groups, respectively (Figure 2) . Similarly, a significant linear trend for %-Inhibition to decrease with greater TB was observed; P=0.018. Of note, neither PRU-Baseline levels nor ARU differed between the 3 groups (P=0.671 and P=0.452, respectively).
In order to detect a cut-off point for PRU levels that best predicts the presence of LTB, a ROC curve analysis was conducted for STB (TB Grade-A and -B) and LTB (TB Grade-C) patients. Area under the curve was calculated to be 0.666 (95% confidence intervals (CI): 0.542-0.791; P=0.014), while PRU levels greater than 251.5 predicted LTB with a 57.9% sensitivity and a 77.8% specificity (Figure 3) .
Furthermore, in order to investigate any possible interactions in the association of PRU levels with TB, multivariate logistic regression analysis was conducted. It was demonstrated that after adjustment for various demographic and clinical characteristics [baseline PRU, ARU, age, gender, smoking, diabetes, dyslipidemia, hypertension, family history, impaired Killip class (≥III), renal failure (glomerular filtration rate <45 ml/min), pain-to-presentation time, FMC-to-balloon time, prior medication with aspirin, clopidogrel, angiotensin converting enzyme-inhibitors (ACEI), β-blockers, statins], PRU result levels greater than 251.5 (odds ratio [OR]=39.27; P=0.002), baseline PRU (OR=0.98; P=0.014), female gender (OR=132.6; P=0.003) and hypertension (OR=0.11; P=0.020) are independent determinants of thrombus Grade C (LTB) ( Table 2) .
A ROC curve analysis to identify cut-off points in PRU baseline that predicts STB was performed. No cut-off point was identified; area under the curve was 0.463 (P=0.588).
Post-PCI Angiographic Perfusion Findings and Platelet Inhibition by Clopidogrel
Patients who manifested normal Post-PCI TIMI-flow (Grade 3) had significantly lower PRU levels compared to those with impaired Post-PCI TIMI-flow (Grades 0,1,2) (179.8±103.4 vs. 277.4±98.1, respectively; P<0.001) ( Table 3 ). This association remained significant (P=0.023) after adjustment with various parameters (baseline PRU, ARU, TB, age, gender, smoking, diabetes mellitus, dyslipidemia, hypertension, family history, pain-to-presentation time, FMC-to-balloon time, prior medication with aspirin, clopidogrel, ACEI, β-blockers, statins).
Similarly, patients with normal MB (Grade 3) had significantly lower PRU levels compared to those with impaired MB (Grades 0,1,2) (160.6±98.5 vs. 271.2±99.3, respectively; P<0.001) ( Table 4 ). This correlation remained statistically 
Discussion
It is well documented that the presence of coronary thrombus has an adverse effect on clinical outcome in patients with ACS undergoing PCI. 19 In our study, we demonstrated that in patients presented with STEMI undergoing unexpectedly delayed primary PCI, the angiographic detection of large TB in the culprit vessel was associated with greater RPR. We studied this population because despite the goal for a pPCI within 2 h from FMC, in a significant number of patients, this time window is surpassed. 14 In this population, inadequate platelet inhibition might further compromise the success of any delayed coronary intervention. Indeed, we found a relationship between inadequate platelet inhibition after clopidogrel loading (expressed by increased PRU levels) and TB, which was documented in patients with STEMI but with a delayed pPCI. Therefore, our findings provide us with a pathophysiological link of the previously reported association between adverse outcomes and high PRU levels after stenting in patients with ACS. 12, 20 In support of the importance and significance of the amount of the angiographically detected thrombus is the fact that a good association of normal Post-PCI TIMI-flow with lower PRU levels after clopidogrel loading was revealed. Indeed, the existence of LTB and the inadequate inhibition of platelets, as detected by PRU measurements, could have resulted in thrombus embolization and coronary flow compromise, which might have led to a worse TIMI-flow. Moreover, we found that normal post-PCI MB was related to lower PRU levels. This finding might be explained, assuming that PCI is performed in a thrombus-rich environment such as the one in our study patients (with LTB), and it would result in a significant amount of micro-embolisation, which could potentially be augmented by the presence of increased RPR. Furthermore, thrombus micro-emboli, after distal migration to the coronary microcirculation, could possibly be further organized and produce further accumulation of thrombus in the micro-vascular environment when higher RPR is present. Indeed, platelet aggregation and augmented thrombus have been implicated in the pathophysiology of no-reflow after primary PCI. 21 In our study, the cut-off value of PRU >251.5 showed a 58% sensitivity and a 78% specificity for predicting LTB. However, in previous studies, PRU values on clopidogrel therapy had better sensitivity than specificity in predicting ischemic cardiac endpoints in patients undergoing non-urgent PCI (81% sensitivity and 53% specificity in the ARMYDA-PRO study 20 ). This discrepancy might be due to several reasons, including the fact that patients undergoing primary PCI were not included in that study. In addition, in patients with AMI and who underwent primary PCI, hemodynamic parameters and local rheological factors might play an important role in the development of LTB, therefore leading to a lower sensitivity for PRU values on clopidogrel treatment.
According to our results, baseline PRU seemed to have a protective role for LTB (OR: 0.98, 95%CI: 0.96-1; P=0.014).
Although this seems rather paradoxical, one may think that patients with a higher baseline PRU presenting with AMI might represent a subset of patients with AMI, in whom platelet tendency for aggregation might have played a more active role in the development of AMI than hemodynamic, local rheological and other plaque-related factors. As a result, a therapy targeting adequate platelet inhibition, by dual antiplatelet therapy, might have manifested a more profound benefit on angiographic thrombus formation.
Clinical Implications
This study provides a pathophysiological connection between platelet inhibition and angiographic TB with myocardial blood flow and myocardial perfusion in patients with STEMI undergoing an unexpectedly delayed pPCI (FMC-to-balloon >2 h). It could be speculated that improvement in these parameters might be achieved through targeting higher platelet inhibition. Our study points to the direction that this could be accomplished by achieving adequate platelet inhibition; adding an IIb/IIIa inhibitor early in the treatment of these patients could possibly be a suggestion.
Newer antiplatelet agents might provide a better option in STEMI patients. Indeed, the TRITON -TIMI 38 trial 22 showed that more intense platelet inhibition resulted in lower ischemic events in high-risk ACS patients undergoing PCI. This is particularly important in STEMI patients where platelet reactivity tends to be higher and the time between symptom onset and PCI is short. Thus, in these patients, prasugrel should be strongly considered. However, the benefit of prasugrel should always be weighed against a higher bleeding risk.
Of course, bed-side measurement by point-of-care assays, like the VerifyNow system, seems to be useful enough, although it's claimed use needs to be further proven in adequately powered randomized trials. 23 Recent studies support the role of adequate platelet inhibition by demonstrating better outcome in patients treated with new and more potent antiplatelet therapies. 24 Our results are in accordance with previous reports regarding the clinical importance of measuring RPR after clopidogrel loading. 12 In addition, the concept of inadequate platelet inhibition by clopidogrel should be considered for risk-stratification after STEMI, especially in patients prone to arterial and stent thrombosis, such as those with diabetes mellitus.
Study Limitations
TB estimation, using coronary angiography, is somehow a subjective procedure, as well as the MB classification. We could have used angioscopy or optical coherence tomography in order to evaluate TB more accurately, but this might have augmented distal embolization and affect TIMI-flow and MB. Nevertheless, because coronary angiography is the most widely used imaging modality for decision making during PCI, we used it as our tool for thrombus classification. In that respect, the classification of thrombus we used is clinically useful and easy to define.
Conclusions
Our study documents the role of platelet inhibition in the angiographically detected coronary TB in patients presented with STEMI, as well as in myocardial flow and perfusion after an unexpectedly delayed primary PCI. It provides a potential mechanism that could explain the association between PRU and adverse outcome in these patients. We report that among patients who presented with STEMI, those with larger coro-
